Dec. 11 at 12:39 AM
JAMA: GLP-1 receptor agonists were linked to a small long-term reduction in vertebral fractures in a cohort study.
The retrospective study was based on electronic health records of people w/ type 2 diabetes.
Prospective studies are needed to confirm causality & elucidate underlying mechanisms.
Overall, these findings support a potential bone protective role of GLP-1 RAs
Initially, GLP-1 receptor agonists like semaglutide (Ozempic, Rybelsus) were used for glucose lowering in type 2 diabetes alone. Then came an influx of landmark studies that linked these medications to weight loss & heart & kidney benefits, among other protective effects. The growing list of FDA-approved indications for GLP-1 medications -- most recently, oral semaglutide for cardiovascular prevention -- has resulted in a steady increase in people without type 2 diabetes using these medications.
$NVO $LLY $PFE $VKTX $ALT